Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical MNCs Moving Full R&D Operations To China

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson recently inaugurated its Asia pharmaceutical R&D Center in Shanghai (PharmAsia News, April 17, 2009), putting China on par with its North American and European R&D bases. The firm attributes the move to not only cost considerations but also to China's huge disease pool and high-quality researchers. The 2004 to 2006 period saw pharmaceutical giants including Pfizer, GSK, Novartis and Sanofi-Aventis setting up their R&D centers in the country. With continuous development, MNCs are gradually moving from merely conducting clinical trials to completing their entire R&D process in the country. However, most life sciences innovations still come from Western countries and Japan as the lack of IP protection hampers China's bid to become a global hub for innovative pharma R&D. (Click here for more - Chinese language)

You may also be interested in...

J&J Expands R&D Force In Asia With Opening Of Shanghai R&D Center

SHANGHAI - Johnson & Johnson opened its Asia Pharmaceutical Research and Development Center in Shanghai April 16

What Did Americans Buy With Stimulus Checks? E.l.f. Beauty Products, For One Thing

In the current economy, e.l.f.’s value messaging is resonating with new consumers, contributing to an 8% jump in its fiscal 2021 first-quarter sales. The company expects continued volatility, but is optimistic about its robust digital game, growing skin-care clout and a newly announced partnership with Alicia Keys that it says will yield much more than “just another celebrity beauty line.”

QUOTED. 11 August 2020. Bryan Hanson.

Most of the major orthopaedics companies beat analyst expectations in the second quarter, but the ongoing COVID-19 pandemic raises uncertainties regarding procedure volumes for the rest of this year. See what Zimmer Biomet’s CEO Bryan Hanson said about it here.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts